Nextage Therapeutics Ltd
Nextage Therapeutics Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. It offers CellDetect, a diagnostic platform for early cancer detection, including bladder cancer, cervical cancer, and prostate cancer. The company also provides BRONJ Test, a test for bisphosphonate-related osteonecrosis of the jaw. In addition, it offers gene expression, and biomark… Read more
Nextage Therapeutics Ltd (MCTC) - Total Liabilities
Latest total liabilities as of June 2020: ILA2.91 Million ILA
Based on the latest financial reports, Nextage Therapeutics Ltd (MCTC) has total liabilities worth ILA2.91 Million ILA as of June 2020.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nextage Therapeutics Ltd - Total Liabilities Trend (2002–2019)
This chart illustrates how Nextage Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Nextage Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Nextage Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DaikyoNishikawa Corp
F:DK8
|
Germany | €77.97 Billion |
|
PZ Cussons PLC
LSE:PZC
|
UK | GBX410.50 Million |
|
Dividend Select 15 Corp
PINK:DVVDF
|
USA | $228.85 Million |
|
PFERDEWETTEN AG
STU:EMH1
|
Germany | €43.12 Million |
Liability Composition Analysis (2002–2019)
This chart breaks down Nextage Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nextage Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nextage Therapeutics Ltd (2002–2019)
The table below shows the annual total liabilities of Nextage Therapeutics Ltd from 2002 to 2019.
| Year | Total Liabilities | Change |
|---|---|---|
| 2019-12-31 | ILA2.35 Million | -67.02% |
| 2018-12-31 | ILA7.12 Million | -10.46% |
| 2017-12-31 | ILA7.96 Million | -12.21% |
| 2016-12-31 | ILA9.06 Million | +12.12% |
| 2015-12-31 | ILA8.08 Million | -13.16% |
| 2014-12-31 | ILA9.31 Million | +9.96% |
| 2013-12-31 | ILA8.47 Million | +3.57% |
| 2012-12-31 | ILA8.17 Million | +53.91% |
| 2011-12-31 | ILA5.31 Million | +282.09% |
| 2010-12-31 | ILA1.39 Million | +22.68% |
| 2009-12-31 | ILA1.13 Million | +264.31% |
| 2008-12-31 | ILA311.00K | -94.29% |
| 2003-12-31 | ILA5.45 Million | -4.72% |
| 2002-12-31 | ILA5.71 Million | -- |